Clinical Trial Update: Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluated irinotecan hydrochloride with or without alvocidib in advanced stomach and gastroesophageal junction cancers; results were co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Gastroesophageal Junction
• Diffuse Adenocarcinoma of the Stomach
• Gastric Cancer
• Intestinal Adenocarcinoma of the Stomach
• Mixed Adenocarcinoma of the Stomach
• Stage Iiia Gastric Cancer
• Stage Iiib Gastric Cancer

Drugs mentioned

• Alvocidib (Flavopiridol)
• Irinotecan (Irinotecan)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach | Phase 2 | Status: COMPLETED | Results posted: 2014-01-21